Form 4: Procept BioRobotics Director Acquires Shares

Director Frederic H. Moll of Procept BioRobotics Corp. reported the acquisition of 3,315 shares of common stock and the grant of 5,853 stock options on June 9, 2026.

Summary

• Frederic H. Moll, a Director at Procept BioRobotics Corp. (PRCT), has reported a transaction involving company securities.
• On June 9, 2026, Moll acquired 3,315 shares of common stock at a price of $0.
• Additionally, on the same date, Moll was granted a stock option to purchase 5,853 shares of common stock at an exercise price of $28.78.
• The restricted stock units (RSUs) vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting, contingent on continued service.
• The stock option also vests in full under the same conditions as the RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine equity awards and acquisitions by a director, which are standard disclosures and do not inherently signal significant positive or negative shifts in the company's performance.

Positives

• Director Frederic H. Moll has acquired additional equity in Procept BioRobotics Corp., indicating confidence in the company's future.
• The grant of stock options suggests a long-term incentive structure for management and directors, aligning their interests with shareholders.
• The acquisition of shares at $0 price for RSUs implies a form of compensation or award.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The vesting of RSUs and stock options is contingent on continued service, meaning potential forfeiture if the director departs.
• The exercise price of the stock option ($28.78) is a potential benchmark for future stock performance; if the stock price remains below this, the options may not be exercised.
• As with any equity-based compensation, the value is subject to market fluctuations and company performance.

Future Outlook

The vesting conditions for the RSUs and stock options suggest a forward-looking incentive tied to continued service and potential future stock price appreciation.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common in the biotechnology and medical device sectors. These filings provide transparency into executive compensation and potential insider confidence in the company's prospects.

Stakeholder Impact

• Shareholders: The transaction provides insight into executive compensation and potential insider confidence, which can indirectly influence investor sentiment.
• Employees: The stock option grant structure may be indicative of broader employee incentive programs.
• Management/Directors: The transaction directly impacts the beneficial ownership and potential future wealth of Director Frederic H. Moll.

Next Steps

• Vesting of RSUs and stock options subject to continued service through the applicable vesting dates.
• Potential exercise of stock options if the stock price exceeds the exercise price of $28.78.

Key Dates

Keywords

Procept BioRobotics, PRCT, Form 4, SEC Filing, Director Transaction, Stock Options, Restricted Stock Units, Beneficial Ownership, Equity Award, Insider Trading